ICU Sedation: Dexmedetomidine (Precedex) Study Notes

General Overview

• Name: Dexmedetomidine (trade name: Precedex)

• Class: Selective α2-adrenergic agonist (similar to clonidine)

• FDA Approval: 1999 for short-term sedation (<24h) in mechanically ventilated ICU patients

• Recent FDA Updates:

  • 2022: Sublingual dissolvable film/tablet approved for acute agitation in schizophrenia or bipolar disorder

• Key Advantage: Sedates without respiratory depression

• Mechanism:

  • Acts centrally on α2 receptors → negative feedback → ↓ norepinephrine release

  • Inhibits neuronal firing → sedation & analgesia

  • Enhances GABA inhibitory activity indirectly (unlike propofol/benzodiazepines)

  • Sedation mimics natural sleep, less amnesia

Therapeutic Actions

• CNS Effects: Sedation, analgesia

• Cardiovascular Effects: ↓ norepinephrine release → may cause bradycardia, hypotension

• Other Actions: Used in ICU and procedural sedation, extubation, awake procedures

Indications

FDA-Approved:

1. Short-term sedation for mechanically ventilated ICU patients

2. Sedation for non-intubated patients during procedures

3. Sublingual film/tablet: acute agitation (schizophrenia/bipolar)

Off-Label Uses:

• Awake craniotomy/intubation

• Prevent post-anesthetic shivering

• Enhance sedation/analgesia in general anesthesia

• Maintain sedation through extubation

• Prolong peripheral nerve block effects

• Alcohol withdrawal management

• Manage cardiovascular effects in amphetamine/cocaine overdose

Contraindications / Cautions

• Absolute: Hypersensitivity to Dexmedetomidine

• Relative / Caution:

  • Healthy adults with high vagal tone

  • Older adults

  • Hepatic impairment

  • Advanced heart blocks, severe ventricular dysfunction

  • Hypovolemia, hypotension

  • Chronic hypertension, diabetes

Adverse Effects (System-Based)

System	Adverse Effects
CNS	Fever, agitation, anxiety, chills, rigors
CV	Hypotension, hypertension, bradycardia, atrial fibrillation, tachycardia, VT
ENT	Dry mouth
GI	Nausea, vomiting, increased thirst, constipation
GU	Oliguria, decreased urine output, acute renal failure
Hematologic	Anemia, bleeding
Metabolic	Hyper/hypoglycemia, hypocalcemia, hypomagnesemia, acidosis
Respiratory	Atelectasis, pleural effusion, hypoxia, pulmonary edema, respiratory failure, ARDS

Most adverse effects are rare but should be monitored.

Formulations & Concentrations

• Common: 4 mcg/mL (max for administration)

• Examples of IV preparations:

  • 400 mcg / 100 mL NS

  • 200 mcg / 50 mL NS

  • 80 mcg / 20 mL NS

  • High-rate mixes possible (e.g., 1000 mcg / 250 mL)

Dosing Guidelines

• Loading Dose (optional): 1 mcg/kg over 10 min → monitor for bradycardia/hypotension

• Maintenance Infusion: 0.2–1.4 mcg/kg/hr → titrate to desired sedation level (RASS)

• Notes: Dose varies by institution; may be used with or without loading dose

Pharmacokinetics

• Onset: Rapid

• Metabolism: Liver

• Excretion: Urine

• Antidote: None

Nursing Considerations

• Must be administered by trained personnel in procedural sedation

• Monitoring:

  • BP, HR, rhythm

  • Respirations & airway integrity

  • Continuous pulse oximetry

• Interventions for hypotension/bradycardia:

  • Reduce/stop infusion

  • IV fluids

  • Leg elevation

  • Vasopressors if necessary

• Patients may remain arousable and alert during infusion

• Mechanical ventilation often not required due to minimal respiratory depression

Laboratory Monitoring

• May cause:

  • ↑ BUN, Na⁺, K⁺, LFTs (AST/ALT, GGT, bilirubin)

  • ↓ Ca²⁺, Mg²⁺, RBC count

  • ↑/↓ glucose

Key Points

• Provides calm, effective sedation in select patients

• Can be used through extubation and post-extubation for agitated patients

• Works differently from typical sedatives; less respiratory compromise

• Dose titration and monitoring are critical for safety